Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
69 hedge funds and large institutions have $335M invested in Harpoon Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 6 closing their positions.
267% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 6
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
50% more capital invested
Capital invested by funds: $223M → $335M (+$112M)
30% more funds holding
Funds holding: 53 → 69 (+16)
3.55% more ownership
Funds ownership: 77.28% → 80.84% (+3.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$18.8M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$13.2M |
| 3 |
BlackRock
New York
|
+$3.08M |
| 4 |
Millennium Management
New York
|
+$1.84M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$964K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$9.53M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.86M |
| 3 |
AG
Artal Group
Luxembourg
|
-$4.68M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$2.37M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$2.21M |
HARP Hedge Fund Activity: Q2 2020 in Review
69 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q2 2020, worth a combined $335M — up 50% from $223M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new HARP positions and 6 closed out — a net gain of 16 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $18.8M. The largest seller was OrbiMed, cutting an estimated $9.53M.
- 69 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q2 2020, up from 53 in Q1 2020.
- Funds reported $335M of Harpoon Therapeutics, Inc. Common Stock stock for Q2 2020, up 50% quarter-over-quarter.
- 22 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q2 2020 and 6 closed out, a net change of +16 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q2 2020 was Avidity Partners Management, an estimated $18.8M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q2 2020 was OrbiMed, an estimated $9.53M sold.
Based on aggregated 13F filings for Q2 2020.